Synonyms: Aliqopa® | BAY 80-6946 | BAY80-6946
copanlisib is an approved drug (FDA (2017))
Compound class:
Synthetic organic
Comment: Copanlisib is a phosphoinositide 3-kinase (PI3K) inhibitor [2], preferentially inhibiting PI3Kα and PI3Kβ, and with significant antineoplastic activity [3]. The compound has less potent mTOR activity.
![]() Ligand Activity Visualisation ChartsThese are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts. ✖ |
|
No information available. |
Summary of Clinical Use ![]() |
In September 2017, copanlisib received FDA approval for the treatment of adults with relapsed follicular lymphoma who have received at least two prior systemic treatments. The EMA granted orphan drug designation for copanlisib in August 2018, as a treatment for marginal zone lymphoma [1]. |